Instil Bio, ImmuneOnco Ink License And Collaboration Agreement; Immuneonco To Receive Upfront Payment, Potential Near-term Payments Of Up To $50M Plus Potential Milestones Exceeding $2B
Portfolio Pulse from Benzinga Newsdesk
Instil Bio and ImmuneOnco have entered into a license and collaboration agreement. Instil Bio will in-license ex-China development and commercial rights to ImmuneOnco's PD-L1xVEGF bispecific antibody, IMM2510, and next-generation anti-CTLA-4 antibody, IMM27M. ImmuneOnco will receive an upfront payment, potential near-term payments up to $50 million, and potential milestones exceeding $2 billion.
August 01, 2024 | 10:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Instil Bio has entered into a significant license and collaboration agreement with ImmuneOnco, acquiring ex-China rights to two of ImmuneOnco's antibodies. This deal includes an upfront payment, potential near-term payments up to $50 million, and potential milestones exceeding $2 billion.
The collaboration and licensing agreement is a significant development for Instil Bio, potentially enhancing its product pipeline and future revenue streams. The financial terms indicate a substantial investment and potential for high returns, which is likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100